本帖最后由 老马 于 2012-1-13 21:20 编辑 . i: }1 g; Y$ Y* g! Y* U! p
$ [5 a0 u# d9 j1 @4 K# ~
爱必妥和阿瓦斯丁的比较/ N6 a. v$ i& A4 [9 g1 C
% |" ^$ T5 P) Y: \+ f X
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
. Y8 i7 L- M$ g
1 W6 D$ Y+ N5 _2 [6 b/ ?
- G5 ~5 I" J' {- Lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& d6 {' G* J6 J/ M0 P
==================================================7 H( W) p& R, [$ N# u$ ^ u
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ {+ v2 {4 A7 C- f+ R4 I
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 u! Y& N6 |& P5 G* _8 o9 EResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* | U0 I9 y* q) ?7 {# I
|
显身卡
